Puma Biotech (PBYI) Misses Q1 EPS by 4c, provides guidance

Puma Biotech (NASDAQ: PBYI) reported Q1 EPS of ($0.04), $0.04 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $44.8 million versus the consensus estimate of $49 million.

GUIDANCE:

Puma Biotech sees Q2 2026 revenue of $52-55 million, versus the consensus of $52 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Sanuwave Q2 2026 revenue tops revised guidance range
• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Syntholene Energy plans $1.5M private placement at $0.45 per unit